System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Jan P van Meerbeeck is an expert in Oncology at Antwerp University Hospital (Belgium). As of October 2026, ScienceLeadR ranks Jan P van Meerbeeck in the top 1% of experts worldwide for Mesothelioma, Adenoma and Thoracic Neoplasms. Jan P van Meerbeeck has authored 388 publications, the most recent in 2026, and is an investigator in 21 clinical trials, 1 of them ongoing. SLR score: 1,366 (community average: 125). How the SLR is computed.

LeadR Profile

Jan P van Meerbeeck Antwerp University Hospital Belgium
1 366 ScienceLeadR Reputation 1366

Unlock

Register Login
Network Map

Oncology

Subspecialties: Pulmonology - Pharmacy - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1996 - 2026
Source: PubMed

Antwerp University Hospital

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 388

Citations

Citations: 40 072 1st author: 30 Last author: 94 Unique author: 7

Main journals

J Thorac Oncol 61
Lung Cancer 35
Eur Respir J 27
Eur J Cancer 15
J Clin Oncol 14

Best Journals

Lancet Oncol 10
Lancet 4
J Clin Oncol 3

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Smoking-related stigma as a barrier to participation in lung cancer screening.
PMID 42573417 — lung, neoplasms, lung neoplasms, smoke, smoking		Eur J Cancer Prev20260
Differentiating benign and malignant solitary pulmonary nodules through exhaled breath analysis.
PMID 41704718 — lung, neoplasms, lung neoplasms, solitary pulmonary nodule		ERJ Open Res20260
Staging of Lung Cancer: A Call for Developing Uniform and Universal Key Performance Indicators and Benchmarks to Elevate Clinical Standards.
PMID 41651572 — lung, neoplasms, lung neoplasms, benchmarking		J Thorac Oncol20260
Hypoxia induces alterations in the volatile signature of pleural mesothelioma cells.
PMID 41534436 — cells, mesothelioma, volatile organic compounds, drug therapy, biomarkers, hypoxia, research		Biomed Pharmacother20260
Multi-omic screening for pleural mesothelioma in Asbestos-Exposed Populations: A literature review and Recommendations.
PMID 41512380 — genomics, mesothelioma, multiple chronic conditions, biomarkers, lung neoplasms, metabolomics, proteomics, diagnosis, research		Lung Cancer20260

Clinical Studies 21

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1 Study Chair: 1

By phase:

Phase 2 9
N/A 4
Phase 3 4
Phase 2/Phase 3 2
Phase 1/Phase 2 1
Phase 4 1

By status:

Completed 15
Terminated 3
Active not recruiting 1
Not yet recruiting 1
Unknown 1

By type:

Interventional 20
Observational 1

By Monocentric/Multicentric:

monocentric 7
multicentric2to4 2
multicentric5to9 2
multicentricup10 10

Main Topics

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Artificial Intelligence for Help Non Small Cell Lung Cancer Measure Cancer Biology and Treatment Response Via Imaging
NCT05254132 — cells, intelligence, lung, blood, neoplasms, multiple chronic conditions, carcinoma, non-small-cell lung, biopsy, biomarkers, immunotherapy, lung neoplasms, small cell lung carcinoma, response evaluation criteria in solid tumors, therapeutics, artificial intelligence, liquid biopsy, carcinoma		N/ANot yet recruiting2022

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS